Cisplatin/fluorouracil
Cisplatin/fluorouracil (CF) is a combination chemotherapy regimen pairing two of oncology's most foundational cytotoxic agents: cisplatin, a platinum-based DNA-crosslinking compound, and fluorouracil (5-FU), a fluoropyrimidine antimetabolite that disrupts RNA synthesis and thymidylate synthase activity.
Cisplatin/fluorouracil (CF) is a combination chemotherapy regimen pairing two of oncology's most foundational cytotoxic agents: cisplatin, a platinum-based DNA-crosslinking compound, and fluorouracil (5-FU), a fluoropyrimidine antimetabolite that disrupts RNA synthesis and thymidylate synthase activity. Together, these agents exert complementary mechanisms of cytotoxicity — cisplatin generates intrastrand and interstrand DNA adducts that trigger apoptotic cascades (including activation of BCL2 apoptosis regulator-regulated pathways and cysteine-aspartic acid protease 3), while fluorouracil interferes with nucleotide metabolism and RNA processing. The synergy of these two mechanisms has made CF a backbone regimen across a broad spectrum of squamous cell and adenocarcinoma histologies, including cancers of the head and neck, esophagus, hypopharynx, stomach, cervix, and lung.
Despite its clinical longevity, the CF regimen carries a significant toxicity burden. cisplatin is associated with nephrotoxicity — partly mediated through disruption of proximal tubule metabolic function and TAK1-dependent NF-κB signaling — as well as emetogenicity and neurotoxicity. fluorouracil contributes mucositis, myelosuppression, and cardiotoxicity risk. Platinum resistance, immune escape via CD274 molecule upregulation, and the immunosuppressive tumor microenvironment further limit the regimen's long-term efficacy, driving active investigation into next-generation strategies that augment or replace conventional CF chemotherapy.
Where the papers sit
15 papers from the last 6 months study cisplatin/fluorouracil directly · updated from PubMed 8 Nov 2026
Study type 0 clinical trials · 4 observational · 1 human data · 8 preclinical · 2 unclassified
Themes one subject
Those 15 are all about one subject.
-
Cancer Chemotherapy Responses
Chemotherapy response remains the shared focus across varied cancers, from clinical dosing and toxicity to experimental delivery strategies. Resistance is repeatedly linked to ferroptosis control, ROS signaling, Notch-Nrf2/GPX4, SLC7A11, cancer-associated fibroblasts and noncoding RNAs. Studies also pursue electroporation, regional infusion, novel platinum complexes and natural compounds to improve cytotoxicity. Clinical work emphasizes individualized cisplatin exposure, antiemetic support and fluorouracil-based treatment outcomes.
Papers
The 15 papers from the last 6 months that study cisplatin/fluorouracil directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Cancer Chemotherapy Responses (15)
- Balloon-occluded Alternative Infusion of Fragmented Gelatin Particles of TACE for Hepatocellular Carcinoma Refractory to Atezolizumab-Bevacizumab. Anticancer research · 29 Jun 2026 PMID 42373279
- Efficacy of Hypotonic Cisplatin Treatment After Marginal Resection of Fibrosarcoma: A Preliminary Report. Anticancer research · 29 Jun 2026 PMID 42373275
- Association Between Individualized Estimated Glomerular Filtration Rate and Cumulative Cisplatin Dose in Head and Neck Cancer. Anticancer research · 29 Jun 2026 PMID 42373265
- Novel patient-derived tongue squamous cell carcinoma cell lines from non-smokers: 3D and in vivo models for drug response studies. Medical oncology (Northwood, London, England) · 29 Jun 2026 PMID 42371352
- Downregulation of SLC44A4 in nasopharyngeal carcinoma is associated with malignant progression, B-cell/TLS-related immune features, and sensitivity to DNA-damaging agents. PloS one · 26 Jun 2026 PMID 42361082
- Electroporation as a strategy to improve the efficacy of chemotherapy in neuroblastoma: an in vitro study. Radiology and oncology · 26 Jun 2026 PMID 42359758
- Real-World Survival and Toxicity Outcomes of Fluorouracil With vs. Without Leucovorin in Metastatic Colorectal Cancer. Journal of gastrointestinal cancer · 22 Jun 2026 PMID 42329513
- Heteronemin suppresses chemoresistant oral squamous cell carcinoma cells through ROS-mediated apoptosis and cuproptosis-associated mitochondrial stress. Apoptosis : an international journal on programmed cell death · 18 Jun 2026 PMID 42315805
- Depleting S100A4 in Cancer-Associated Fibroblasts Reverses Cisplatin Resistance in Esophageal Cancer. ACS applied bio materials · 18 Jun 2026 PMID 42313741
- DLL1-mediated ferroptosis resistance via the Notch-Nrf2/GPX4 axis drives cisplatin resistance in ovarian cancer. Cancer & metabolism · 18 Jun 2026 PMID 42310697
- Pt(IV) Complexes Incorporating CDC25A/NF-κB Dual Inhibitory 1,4-Naphthoquinone Derivatives Trigger Multimodal Cell Death in A2780 Ovarian Cancer Cells. Journal of medicinal chemistry · 11 Jun 2026 PMID 42275647
- Can alterations in miR-21, miR-1, and miR-224 expression predict personalized medicine chemotherapy in non-small cell lung cancer? Molecular biology reports · 10 Jun 2026 PMID 42268452
- Antiemetic Efficacy of Aprepitant in Cisplatin-Gemcitabine Therapy for Biliary Tract Cancer: A Multicenter Study. Anticancer research · 27 May 2026 PMID 42203357
- Santamarine Synergizes With Cisplatin via ROS/JNK Axis to Selectively Induce Apoptosis and DNA Damage in Oral Cancer Cells In Vitro. Drug development research · 26 May 2026 PMID 42187533
- Paris polyphylla saponin Ⅱ induces autophagy-associated ferroptosis by regulating the BECLIN1/SLC7A11 axis in cervical cancer. European journal of pharmacology · 20 May 2026 PMID 42162690
By study type
Observational studies and case reports (4)
- Balloon-occluded Alternative Infusion of Fragmented Gelatin Particles of TACE for Hepatocellular Carcinoma Refractory to Atezolizumab-Bevacizumab. Anticancer research · 29 Jun 2026 PMID 42373279
- Association Between Individualized Estimated Glomerular Filtration Rate and Cumulative Cisplatin Dose in Head and Neck Cancer. Anticancer research · 29 Jun 2026 PMID 42373265
- Real-World Survival and Toxicity Outcomes of Fluorouracil With vs. Without Leucovorin in Metastatic Colorectal Cancer. Journal of gastrointestinal cancer · 22 Jun 2026 PMID 42329513
- Antiemetic Efficacy of Aprepitant in Cisplatin-Gemcitabine Therapy for Biliary Tract Cancer: A Multicenter Study. Anticancer research · 27 May 2026 PMID 42203357
Human data, design not indexed (1)
- Can alterations in miR-21, miR-1, and miR-224 expression predict personalized medicine chemotherapy in non-small cell lung cancer? Molecular biology reports · 10 Jun 2026 PMID 42268452
Preclinical: animal, cell and lab studies (8)
- Efficacy of Hypotonic Cisplatin Treatment After Marginal Resection of Fibrosarcoma: A Preliminary Report. Anticancer research · 29 Jun 2026 PMID 42373275
- Novel patient-derived tongue squamous cell carcinoma cell lines from non-smokers: 3D and in vivo models for drug response studies. Medical oncology (Northwood, London, England) · 29 Jun 2026 PMID 42371352
- Downregulation of SLC44A4 in nasopharyngeal carcinoma is associated with malignant progression, B-cell/TLS-related immune features, and sensitivity to DNA-damaging agents. PloS one · 26 Jun 2026 PMID 42361082
- Electroporation as a strategy to improve the efficacy of chemotherapy in neuroblastoma: an in vitro study. Radiology and oncology · 26 Jun 2026 PMID 42359758
- Heteronemin suppresses chemoresistant oral squamous cell carcinoma cells through ROS-mediated apoptosis and cuproptosis-associated mitochondrial stress. Apoptosis : an international journal on programmed cell death · 18 Jun 2026 PMID 42315805
- Pt(IV) Complexes Incorporating CDC25A/NF-κB Dual Inhibitory 1,4-Naphthoquinone Derivatives Trigger Multimodal Cell Death in A2780 Ovarian Cancer Cells. Journal of medicinal chemistry · 11 Jun 2026 PMID 42275647
- Santamarine Synergizes With Cisplatin via ROS/JNK Axis to Selectively Induce Apoptosis and DNA Damage in Oral Cancer Cells In Vitro. Drug development research · 26 May 2026 PMID 42187533
- Paris polyphylla saponin Ⅱ induces autophagy-associated ferroptosis by regulating the BECLIN1/SLC7A11 axis in cervical cancer. European journal of pharmacology · 20 May 2026 PMID 42162690
Unclassified: not yet indexed with MeSH (2)
- Depleting S100A4 in Cancer-Associated Fibroblasts Reverses Cisplatin Resistance in Esophageal Cancer. ACS applied bio materials · 18 Jun 2026 PMID 42313741
- DLL1-mediated ferroptosis resistance via the Notch-Nrf2/GPX4 axis drives cisplatin resistance in ovarian cancer. Cancer & metabolism · 18 Jun 2026 PMID 42310697
Written from 15 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.